Curr Med Res Opin. 2001;17(1s) 

In This Article


Granisetron, ondansetron and tropisetron are potent and highly selective 5-HT3 antagonists. They have no dopamine antagonist properties and so are not associated with extrapyramidal side-effects. Their selective activity made them obvious candidates for migraine.

An open pilot study of granistron administered as a single dose intravenous infusion (40 É g/kg) over 15 minutes to treat seven migraine attacks in six patients. All but one patient experienced marked and rapid relief of headache, nausea and vomiting withnorecurrence[24].

A randomized double-blind placebo-controlled study of 28 acute migraine patients given intravenous granisetron (40 É g/kg or 80 É g/kg) was less successful although the 80 É g/kg dose was associated with significant improvement in headache[25].

Given the limited data and some minor concerns about toxicology with long-term repeated doses, 5-HT3 antagonists should not be used for the routine management of migraine but are reserved for the treatment of post-operative or cytostatically-induced nausea and vomiting.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.